These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

421 related items for PubMed ID: 12817758

  • 1. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate.
    Eastell R, Barton I, Hannon RA, Chines A, Garnero P, Delmas PD.
    J Bone Miner Res; 2003 Jun; 18(6):1051-6. PubMed ID: 12817758
    [Abstract] [Full Text] [Related]

  • 2. Relationship between pretreatment bone resorption and vertebral fracture incidence in postmenopausal osteoporotic women treated with risedronate.
    Seibel MJ, Naganathan V, Barton I, Grauer A.
    J Bone Miner Res; 2004 Feb; 19(2):323-9. PubMed ID: 14969403
    [Abstract] [Full Text] [Related]

  • 3. Relationship between changes in BMD and nonvertebral fracture incidence associated with risedronate: reduction in risk of nonvertebral fracture is not related to change in BMD.
    Watts NB, Geusens P, Barton IP, Felsenberg D.
    J Bone Miner Res; 2005 Dec; 20(12):2097-104. PubMed ID: 16294263
    [Abstract] [Full Text] [Related]

  • 4. Risedronate reduces the risk of first vertebral fracture in osteoporotic women.
    Heaney RP, Zizic TM, Fogelman I, Olszynski WP, Geusens P, Kasibhatla C, Alsayed N, Isaia G, Davie MW, Chesnut CH.
    Osteoporos Int; 2002 Dec; 13(6):501-5. PubMed ID: 12107665
    [Abstract] [Full Text] [Related]

  • 5. Safety and efficacy of risedronate in reducing fracture risk in osteoporotic women aged 80 and older: implications for the use of antiresorptive agents in the old and oldest old.
    Boonen S, McClung MR, Eastell R, El-Hajj Fuleihan G, Barton IP, Delmas P.
    J Am Geriatr Soc; 2004 Nov; 52(11):1832-9. PubMed ID: 15507059
    [Abstract] [Full Text] [Related]

  • 6. Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study.
    Garnero P, Hausherr E, Chapuy MC, Marcelli C, Grandjean H, Muller C, Cormier C, Bréart G, Meunier PJ, Delmas PD.
    J Bone Miner Res; 1996 Oct; 11(10):1531-8. PubMed ID: 8889854
    [Abstract] [Full Text] [Related]

  • 7. Risedronate decreases bone resorption and improves low back pain in postmenopausal osteoporosis patients without vertebral fractures.
    Ohtori S, Akazawa T, Murata Y, Kinoshita T, Yamashita M, Nakagawa K, Inoue G, Nakamura J, Orita S, Ochiai N, Kishida S, Takaso M, Eguchi Y, Yamauchi K, Suzuki M, Aoki Y, Takahashi K.
    J Clin Neurosci; 2010 Feb; 17(2):209-13. PubMed ID: 20044258
    [Abstract] [Full Text] [Related]

  • 8. Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis.
    Harrington JT, Ste-Marie LG, Brandi ML, Civitelli R, Fardellone P, Grauer A, Barton I, Boonen S.
    Calcif Tissue Int; 2004 Feb; 74(2):129-35. PubMed ID: 14648009
    [Abstract] [Full Text] [Related]

  • 9. Five years of treatment with risedronate and its effects on bone safety in women with postmenopausal osteoporosis.
    Ste-Marie LG, Sod E, Johnson T, Chines A.
    Calcif Tissue Int; 2004 Dec; 75(6):469-76. PubMed ID: 15478000
    [Abstract] [Full Text] [Related]

  • 10. Aging bone and osteoporosis: strategies for preventing fractures in the elderly.
    Ettinger MP.
    Arch Intern Med; 2003 Oct 13; 163(18):2237-46. PubMed ID: 14557222
    [Abstract] [Full Text] [Related]

  • 11. Type I collagen racemization and isomerization and the risk of fracture in postmenopausal women: the OFELY prospective study.
    Garnero P, Cloos P, Sornay-Rendu E, Qvist P, Delmas PD.
    J Bone Miner Res; 2002 May 13; 17(5):826-33. PubMed ID: 12009013
    [Abstract] [Full Text] [Related]

  • 12. A comparison of incidences of vertebral fracture in Japanese patients with involutional osteoporosis treated with risedronate and etidronate: a randomized, double-masked trial.
    Kushida K, Fukunaga M, Kishimoto H, Shiraki M, Itabashi A, Inoue T, Kaneda K, Morii H, Nawata H, Yamamoto K, Ohashi Y, Orimo H.
    J Bone Miner Metab; 2004 May 13; 22(5):469-78. PubMed ID: 15316868
    [Abstract] [Full Text] [Related]

  • 13. Assessment of the relationship between age and the effect of risedronate treatment in women with postmenopausal osteoporosis: a pooled analysis of four studies.
    Boonen S, Klemes AB, Zhou X, Lindsay R.
    J Am Geriatr Soc; 2010 Apr 13; 58(4):658-63. PubMed ID: 20345865
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis.
    Chen P, Satterwhite JH, Licata AA, Lewiecki EM, Sipos AA, Misurski DM, Wagman RB.
    J Bone Miner Res; 2005 Jun 13; 20(6):962-70. PubMed ID: 15883636
    [Abstract] [Full Text] [Related]

  • 16. Effects of short-term risedronate on bone resorption and patient satisfaction in postmenopausal osteoporosis patients.
    Fernandes CE, Zerbini C, Russo LA, Albernaz MA, Eis SR, Szejnfeld VL, Pompei LM.
    J Clin Densitom; 2009 Jun 13; 12(1):77-83. PubMed ID: 19004654
    [Abstract] [Full Text] [Related]

  • 17. Effects of 3- and 5-year treatment with risedronate on bone mineralization density distribution in triple biopsies of the iliac crest in postmenopausal women.
    Zoehrer R, Roschger P, Paschalis EP, Hofstaetter JG, Durchschlag E, Fratzl P, Phipps R, Klaushofer K.
    J Bone Miner Res; 2006 Jul 13; 21(7):1106-12. PubMed ID: 16813531
    [Abstract] [Full Text] [Related]

  • 18. Bone material properties in trabecular bone from human iliac crest biopsies after 3- and 5-year treatment with risedronate.
    Durchschlag E, Paschalis EP, Zoehrer R, Roschger P, Fratzl P, Recker R, Phipps R, Klaushofer K.
    J Bone Miner Res; 2006 Oct 13; 21(10):1581-90. PubMed ID: 16995813
    [Abstract] [Full Text] [Related]

  • 19. Reduction in PINP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fracture risk.
    Reginster JY, Sarkar S, Zegels B, Henrotin Y, Bruyere O, Agnusdei D, Collette J.
    Bone; 2004 Feb 13; 34(2):344-51. PubMed ID: 14962813
    [Abstract] [Full Text] [Related]

  • 20. Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover.
    Delmas PD, Licata AA, Reginster JY, Crans GG, Chen P, Misurski DA, Wagman RB, Mitlak BH.
    Bone; 2006 Aug 13; 39(2):237-43. PubMed ID: 16563890
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.